Consorzio Italbiotec, Piazza Della Trivulziana 4/A, 20126 Milano, Italy.
Institute of Biomedical Technologies, National Research Council, Via Fratelli Cervi 93, 20054 Segrate, Italy.
Nutrients. 2022 Jun 28;14(13):2689. doi: 10.3390/nu14132689.
The evaluation of probiotics' efficacy in treating irritable bowel syndrome is supported by an increasing number of clinical studies based on a heterogeneous approach of products tested and the patient cohort involved. Although the role of gut microbiota dysbiosis in IBS pathogenesis and the beneficial contribution of probiotics were demonstrated, a tool to discriminate symptom-specific strains and a personalised medicine protocol are still lacking. Thus, this study employs, for the first time, a method that combines the preferred reporting items for systematic reviews and meta-analysis and multi-criteria decision analysis methods in a structured decision-making tool to analyze the efficacy of probiotic mix, in order to identify the most effective formulation and to discriminate which probiotics are more efficient in treating different symptoms. The PRISMA methodology resulted in a qualitative and quantitative analysis of 104 clinical studies from 2011 to 2021, revealing a prevalence of , and subsp. . MCDA analysis showed that formulations based on and have the highest efficacy, especially on quality of life, bloating, and abdominal pain. This methodological approach could become more specific by modelling clinical studies according to the age and gender of patients and probiotic strain.
越来越多的临床研究基于产品测试和所涉及患者群体的异质方法，支持益生菌治疗肠易激综合征的疗效。虽然肠道微生物失调在 IBS 发病机制中的作用以及益生菌的有益贡献已得到证实，但仍缺乏区分症状特异性菌株和个性化药物治疗方案的工具。因此，本研究首次采用一种方法，将系统评价和荟萃分析的首选报告项目与多准则决策分析方法相结合，应用于结构化决策工具中，以分析益生菌混合制剂的疗效，从而确定最有效的配方，并区分哪些益生菌在治疗不同症状方面更有效。PRISMA 方法对 2011 年至 2021 年的 104 项临床研究进行了定性和定量分析，结果显示 、 和 亚种的流行率较高。多准则决策分析显示，基于 和 的配方具有最高的疗效，特别是在生活质量、腹胀和腹痛方面。这种方法学方法可以通过根据患者的年龄和性别以及益生菌菌株对临床研究进行建模，变得更加具体。
